Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant

Recruiting now · Phase 2/Phase 3

Conditions studied: CMV Viremia, Heart Transplant Infection, Heart Transplant Failure and Rejection

In brief

The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.

Key facts

Study ID

NCT07079735

Run by

Columbia University

People needed

150

Starts

2025-09-12

Expected to finish

2029-01-17

Last updated by the study team

2025-09-25

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who are >18 years of age who have received a heart transplant and have not started their CMV prophylaxis regimen will be included.

You may not qualify if…

• History of or suspected CMV disease within 6 months prior is excluded.

Where it is running

• NYP-Weill Cornell — New York, New York, United States (enrolling)
• Columbia University/NYP Milstein Hospital — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.